These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

302 related items for PubMed ID: 27473087

  • 1. Growth inhibitory effect of rapamycin in Hodgkin-lymphoma cell lines characterized by constitutive NOTCH1 activation.
    Nagy N, Hajdu M, Márk Á, Király PA, Tóth M, Dankó T, Csóka M, Sebestyén A.
    Tumour Biol; 2016 Oct; 37(10):13695-13704. PubMed ID: 27473087
    [Abstract] [Full Text] [Related]

  • 2. PI3K/mTOR inhibition upregulates NOTCH-MYC signalling leading to an impaired cytotoxic response.
    Shepherd C, Banerjee L, Cheung CW, Mansour MR, Jenkinson S, Gale RE, Khwaja A.
    Leukemia; 2013 Mar; 27(3):650-60. PubMed ID: 23038273
    [Abstract] [Full Text] [Related]

  • 3. Characteristic mTOR activity in Hodgkin-lymphomas offers a potential therapeutic target in high risk disease--a combined tissue microarray, in vitro and in vivo study.
    Márk Á, Hajdu M, Váradi Z, Sticz TB, Nagy N, Csomor J, Berczi L, Varga V, Csóka M, Kopper L, Sebestyén A.
    BMC Cancer; 2013 May 22; 13():250. PubMed ID: 23693095
    [Abstract] [Full Text] [Related]

  • 4. Alterations of hypoxia-induced factor signaling pathway due to mammalian target of rapamycin (mTOR) suppression in ovarian clear cell adenocarcinoma: in vivo and in vitro explorations for clinical trial.
    Hirasawa T, Miyazawa M, Yasuda M, Shida M, Ikeda M, Kajiwara H, Matsui N, Fujita M, Muramatsu T, Mikami M.
    Int J Gynecol Cancer; 2013 Sep 22; 23(7):1210-8. PubMed ID: 23899586
    [Abstract] [Full Text] [Related]

  • 5. [Significance of mTOR (mammalian target of rapamycin) activity in human lymphomas].
    Márk Á.
    Magy Onkol; 2014 Jun 22; 58(2):143-8. PubMed ID: 25010764
    [Abstract] [Full Text] [Related]

  • 6. Akt inhibitors MK-2206 and nelfinavir overcome mTOR inhibitor resistance in diffuse large B-cell lymphoma.
    Petrich AM, Leshchenko V, Kuo PY, Xia B, Thirukonda VK, Ulahannan N, Gordon S, Fazzari MJ, Ye BH, Sparano JA, Parekh S.
    Clin Cancer Res; 2012 May 01; 18(9):2534-44. PubMed ID: 22338016
    [Abstract] [Full Text] [Related]

  • 7. Synergism between the mTOR inhibitor rapamycin and FAK down-regulation in the treatment of acute lymphoblastic leukemia.
    Shi PJ, Xu LH, Lin KY, Weng WJ, Fang JP.
    J Hematol Oncol; 2016 Feb 18; 9():12. PubMed ID: 26892465
    [Abstract] [Full Text] [Related]

  • 8. Targeting the Notch1 and mTOR pathways in a mouse T-ALL model.
    Cullion K, Draheim KM, Hermance N, Tammam J, Sharma VM, Ware C, Nikov G, Krishnamoorthy V, Majumder PK, Kelliher MA.
    Blood; 2009 Jun 11; 113(24):6172-81. PubMed ID: 19246562
    [Abstract] [Full Text] [Related]

  • 9. Proteasomal Inhibition by Ixazomib Induces CHK1 and MYC-Dependent Cell Death in T-cell and Hodgkin Lymphoma.
    Ravi D, Beheshti A, Abermil N, Passero F, Sharma J, Coyle M, Kritharis A, Kandela I, Hlatky L, Sitkovsky MV, Mazar A, Gartenhaus RB, Evens AM.
    Cancer Res; 2016 Jun 01; 76(11):3319-31. PubMed ID: 26988986
    [Abstract] [Full Text] [Related]

  • 10. Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade.
    Penna I, Molla A, Grazia G, Cleris L, Nicolini G, Perrone F, Picciani B, Del Vecchio M, de Braud F, Mortarini R, Anichini A.
    Oncotarget; 2016 Jan 26; 7(4):3947-65. PubMed ID: 26678033
    [Abstract] [Full Text] [Related]

  • 11. DLL4 regulates NOTCH signaling and growth of T acute lymphoblastic leukemia cells in NOD/SCID mice.
    Minuzzo S, Agnusdei V, Pusceddu I, Pinazza M, Moserle L, Masiero M, Rossi E, Crescenzi M, Hoey T, Ponzoni M, Amadori A, Indraccolo S.
    Carcinogenesis; 2015 Jan 26; 36(1):115-21. PubMed ID: 25355291
    [Abstract] [Full Text] [Related]

  • 12. A molecular cascade modulates MAP1B and confers resistance to mTOR inhibition in human glioblastoma.
    Laks DR, Oses-Prieto JA, Alvarado AG, Nakashima J, Chand S, Azzam DB, Gholkar AA, Sperry J, Ludwig K, Condro MC, Nazarian S, Cardenas A, Shih MYS, Damoiseaux R, France B, Orozco N, Visnyei K, Crisman TJ, Gao F, Torres JZ, Coppola G, Burlingame AL, Kornblum HI.
    Neuro Oncol; 2018 May 18; 20(6):764-775. PubMed ID: 29136244
    [Abstract] [Full Text] [Related]

  • 13. Regulation of the epithelial to mesenchymal transition and metastasis by Raf kinase inhibitory protein-dependent Notch1 activity.
    Noh HS, Hah YS, Ha JH, Kang MY, Zada S, Rha SY, Kang SS, Kim HJ, Park JY, Byun JH, Hahm JR, Shin JK, Jeong SH, Lee YJ, Kim DR.
    Oncotarget; 2016 Jan 26; 7(4):4632-46. PubMed ID: 26716415
    [Abstract] [Full Text] [Related]

  • 14. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.
    Hales EC, Taub JW, Matherly LH.
    Cell Signal; 2014 Jan 26; 26(1):149-61. PubMed ID: 24140475
    [Abstract] [Full Text] [Related]

  • 15. Curcumin inhibits carcinogen and nicotine-induced Mammalian target of rapamycin pathway activation in head and neck squamous cell carcinoma.
    Clark CA, McEachern MD, Shah SH, Rong Y, Rong X, Smelley CL, Caldito GC, Abreo FW, Nathan CO.
    Cancer Prev Res (Phila); 2010 Dec 26; 3(12):1586-95. PubMed ID: 20851953
    [Abstract] [Full Text] [Related]

  • 16. Rheb1 promotes tumor progression through mTORC1 in MLL-AF9-initiated murine acute myeloid leukemia.
    Gao Y, Gao J, Li M, Zheng Y, Wang Y, Zhang H, Wang W, Chu Y, Wang X, Xu M, Cheng T, Ju Z, Yuan W.
    J Hematol Oncol; 2016 Apr 12; 9():36. PubMed ID: 27071307
    [Abstract] [Full Text] [Related]

  • 17. NOTCH knockdown affects the proliferation and mTOR signaling of leukemia cells.
    Okuhashi Y, Itoh M, Nara N, Tohda S.
    Anticancer Res; 2013 Oct 12; 33(10):4293-8. PubMed ID: 24122995
    [Abstract] [Full Text] [Related]

  • 18. Inhibiting PLK1 induces autophagy of acute myeloid leukemia cells via mammalian target of rapamycin pathway dephosphorylation.
    Tao YF, Li ZH, Du WW, Xu LX, Ren JL, Li XL, Fang F, Xie Y, Li M, Qian GH, Li YH, Li YP, Li G, Wu Y, Feng X, Wang J, He WQ, Hu SY, Lu J, Pan J.
    Oncol Rep; 2017 Mar 12; 37(3):1419-1429. PubMed ID: 28184925
    [Abstract] [Full Text] [Related]

  • 19. Inhibition of p-mTOR represses transcription of PS1 and Notch 1-signaling.
    Das HK, Hontiveros SS.
    Front Biosci (Landmark Ed); 2020 Mar 01; 25(6):1172-1183. PubMed ID: 32114428
    [Abstract] [Full Text] [Related]

  • 20. Targeting Notch signaling by γ-secretase inhibitor I enhances the cytotoxic effect of 5-FU in gastric cancer.
    Lee HW, Kim SJ, Choi IJ, Song J, Chun KH.
    Clin Exp Metastasis; 2015 Aug 01; 32(6):593-603. PubMed ID: 26134677
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.